CTMX
Income statement / Annual
Last year (2025), CytomX Therapeutics Inc's total revenue was $76.20 M,
a decrease of 44.82% from the previous year.
In 2025, CytomX Therapeutics Inc's net income was -$17.37 M.
See CytomX Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$76.20 M |
$138.10 M |
$101.21 M |
$53.16 M |
$37.31 M |
$68.43 M |
$57.49 M |
$59.50 M |
$71.62 M |
$15.04 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$76.20 M
|
$138.10 M
|
$101.21 M
|
$53.16 M
|
$37.31 M
|
$68.43 M
|
$57.49 M
|
$59.50 M
|
$71.62 M
|
$15.04 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$68.73 M
|
$83.38 M
|
$77.68 M
|
$111.65 M
|
$114.19 M
|
$112.94 M
|
$131.62 M
|
$103.87 M
|
$92.28 M
|
$54.76 M
|
| General & Administrative Expenses |
$29.84 M
|
$29.73 M
|
$30.02 M
|
$42.85 M
|
$39.16 M
|
$36.03 M
|
$36.77 M
|
$33.51 M
|
$25.61 M
|
$19.87 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$29.84 M
|
$29.73 M
|
$30.02 M
|
$42.85 M
|
$39.16 M
|
$36.03 M
|
$36.77 M
|
$33.51 M
|
$25.61 M
|
$19.87 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$135.00 K
|
-$68.00 K
|
-$27.00 K
|
-$69.00 K
|
| Operating Expenses |
$98.57 M
|
$113.11 M
|
$107.70 M
|
$154.50 M
|
$153.35 M
|
$148.97 M
|
$168.38 M
|
$137.38 M
|
$117.88 M
|
$74.63 M
|
| Cost And Expenses |
$98.57 M
|
$113.11 M
|
$107.70 M
|
$154.50 M
|
$153.35 M
|
$148.97 M
|
$168.38 M
|
$137.38 M
|
$117.88 M
|
$74.63 M
|
| Interest Income |
$5.21 M
|
$7.14 M
|
$9.84 M
|
$1.68 M
|
$255.00 K
|
$1.84 M
|
$8.37 M
|
$7.64 M
|
$2.67 M
|
$2.43 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.69 M
|
| Depreciation & Amortization |
$1.38 M
|
$1.77 M
|
$2.18 M
|
$2.44 M
|
$2.71 M
|
$2.57 M
|
$2.61 M
|
$1.88 M
|
$1.65 M
|
$1.73 M
|
| EBITDA |
-$20.99 M |
$26.76 M |
-$4.31 M |
-$98.89 M |
-$113.34 M |
-$77.97 M |
-$100.06 M |
-$75.99 M |
-$41.97 M |
-$57.85 M |
| EBITDA Ratio |
-0.28
|
0.19
|
-0.04
|
-1.86
|
-3.04
|
-1.14
|
-1.74
|
-1.28
|
-0.59
|
-3.85
|
| Operating Income Ratio |
-0.29
|
0.18
|
-0.06
|
-1.91
|
-3.11
|
-1.18
|
-1.93
|
-1.31
|
-0.65
|
-3.96
|
| Total Other Income/Expenses Net |
$5.23 M
|
$7.10 M
|
$9.81 M
|
$2.02 M
|
$172.00 K
|
$29.63 M
|
$8.23 M
|
$7.57 M
|
$2.65 M
|
$667.00 K
|
| Income Before Tax |
-$17.13 M
|
$32.09 M
|
$3.32 M
|
-$99.32 M
|
-$115.87 M
|
-$50.91 M
|
-$102.67 M
|
-$70.30 M
|
-$43.61 M
|
-$58.92 M
|
| Income Before Tax Ratio |
-0.22
|
0.23
|
0.03
|
-1.87
|
-3.11
|
-0.74
|
-1.79
|
-1.18
|
-0.61
|
-3.92
|
| Income Tax Expense |
$238.00 K
|
$224.00 K
|
$3.89 M
|
$0.00
|
$0.00
|
$13.91 M
|
-$427.00 K
|
$14.30 M
|
-$513.00 K
|
-$19.00 K
|
| Net Income |
-$17.37 M
|
$31.87 M
|
-$569.00 K
|
-$99.32 M
|
-$115.87 M
|
-$64.82 M
|
-$102.24 M
|
-$84.60 M
|
-$43.10 M
|
-$58.90 M
|
| Net Income Ratio |
-0.23
|
0.23
|
-0.01
|
-1.87
|
-3.11
|
-0.95
|
-1.78
|
-1.42
|
-0.6
|
-3.92
|
| EPS |
-0.15 |
0.38 |
-0.0077 |
-1.48 |
-1.26 |
-0.71 |
-2.26 |
-2.03 |
-1.16 |
-1.63 |
| EPS Diluted |
-0.15 |
0.38 |
-0.0077 |
-1.48 |
-1.26 |
-0.71 |
-2.26 |
-2.03 |
-1.16 |
-1.63 |
| Weighted Average Shares Out |
$137.94 M
|
$84.44 M
|
$73.81 M
|
$65.74 M
|
$64.15 M
|
$46.15 M
|
$45.34 M
|
$41.66 M
|
$37.17 M
|
$36.23 M
|
| Weighted Average Shares Out Diluted |
$137.94 M
|
$84.75 M
|
$73.81 M
|
$65.74 M
|
$64.15 M
|
$46.15 M
|
$45.34 M
|
$41.66 M
|
$37.17 M
|
$36.23 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
